Event Calendar

Upcoming Events
There are currently no events scheduled.
Past Events
DateTitle
March 14, 2017 2:05 p.m. ET
Exelixis, Inc. at the Barclays Global Healthcare Conference 2017
March 07, 2017 10:40 a.m. ET
Exelixis, Inc. at the Cowen and Company 37th Annual Health Care Conference
February 27, 2017 5:00 p.m. ET
Q4/FY 2016 Exelixis Inc. Financial Results Conference Call
Supporting Materials
Download Event Supporting Material  Exelixis Q4 2016 Financial Results
November 03, 2016 5:00 p.m. ET
Q3 2016 Exelixis Inc. Financial Results Conference Call
Supporting Materials
Download Event Supporting Material Exelixis Q3 2016 Financial Results
October 10, 2016 1:00 p.m. ET
Exelixis, Inc. at the European Society for Medical Oncology (ESMO) 2016 Congress
Description

Exelixis co-hosted an investor and media briefing at the ESMO 2016 Congress. During the 90 minute event, the company’s management team and invited guests reviewed data for cabozantinib presented at ESMO, including the results of the CABOSUN phase 2 randomized trial. The event also included a panel discussion with Drs. Toni K. Choueiri (Dana-Farber), Nizar Tannir (MD Anderson Cancer Center) and Sumanta Pal (City of Hope).

Supporting Materials
Download Event Supporting Material European Society for Medical Oncology (ESMO) 2016 Congress Presentation
Download Event Supporting Material Audio File
August 03, 2016 5:00 p.m. ET
Q2 2016 Exelixis Inc. Financial Results Conference Call
Supporting Materials
Download Event Supporting Material Exelixis Q2 2016 Financial Results
June 05, 2016 6:30 p.m. CT
Exelixis, Inc. 2016 ASCO Investor Briefing
Supporting Materials
Download Event Supporting Material ASCO Investor Briefing Presentation
May 04, 2016 5:00 p.m. ET
Q1 2016 Exelixis Inc. Financial Results Conference Call
Supporting Materials
Download Event Supporting Material Exelixis Q1 2016 Financial Results
April 25, 2016 4:00 p.m. ET
Exelixis, Inc. Conference Call to Discuss U.S. FDA Approval of CABOMETYX (Cabozantinib) Tablets
Supporting Materials
Download Event Supporting Material Exelixis U.S. FDA Approval of CABOMETYX (Cabozantinib) Tablets Presentation